Emvision Medical Devices Ltd. · ASX:EMV
Emvision Medical Devices — Shareholder Meeting (November 2019)
12 slides from Emvision Medical Devices's shareholder meeting presentation, Nov 26, 2019
Slide 1: AGM – Chairman's Address & CEO Presentation
26/11/19 EMVision Medical Devices Ltd ACN 620 388 230 Level 10, 12 Creek Street, Brisbane Qld 4000 02 8667 5337 contact@emvision.com.au For personal use only AGM – CHAIRMAN’S ADDRESS & CEO PRESENTATION EMVision Medical Devices Limited (ASX: EMV) (“EMVision” or the “Company”) announces the following
Slide 2: About EMVision Medical Devices
For further information, media or investor enquiries, please contact: Michael Wills Scott Kirkland Investor & Media Relations Executive Director +61 468 385 208 +61 2 8667 5337 michael@spring-communications.com.au skirkland@emvision.com.au For personal use only About EMVision Medical Devices EMVisio
Slide 3: CEO Presentation – Annual General Meeting
www.emvision.com.au For personal use only CEO PRESENTATION Annual General Meeting
Slide 4: Disclaimer
DISCLAIMER For personal use only This presentation has been prepared by Emvision Medical Devices Limited (“EMVision” or “the Company”). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securiti
Slide 5: EMV is developing breakthrough portable diagnostics
EMV IS DEVELOPING BREAKTHROUGH PORTABLE DIAGNOSTICS Portable Non-ionising Miniaturized Cost Effective Non-invasive Powerful functional imaging capabilities hardware For personal use only Electromagnetic Radio Frequency (RF) is a truly innovative imaging modality that has disruptive implications for
Slide 6: Team
TEAM Significant experience developing and commercialising medical devices For personal use only Dr Ron Weinberger John Keep Scott Kirkland Prof Stuart Crozier Robert Tiller Chief Executive Officer Executive Chairman Executive Director Clinical Development Advisor Product Design & Former Exec Direct
Slide 7: Clinical Advisory Board
CLINICAL ADVISORY BOARD EMvision has secured advisors with world-leading experience in diagnosing and treating For personal use only neurological disorders. The composition and Brisbane location of the group has been specifically engineered to aid in delivering a successful clinical trial program. “
Slide 8: 2019 Highlights
2019 HIGHLIGHTS For personal use only CLINICAL UNIT System integrated, built and tested by a broad range BUILD COMPLETE of clinicians for hospital workflow suitability and usability. ETHICS Incudes both operator and patient safety as well as CLEARANCE AND ensuring no interference with other medical
Slide 9: 2019 Collaboration Update
2019 COLLABORATION UPDATE For personal use only Collaboration continues to strengthen in The team continues to make excellent EMVision joined the NVIDIA Corporation preparation for a Stage 2 Frontiers Bid progress towards a compact and cost effective (NASDAQ:NVDA) Inception Program, an anticipated f
Slide 10: Clinical trial progressing to plan
CLINICAL TRIAL PROGRESSING TO PLAN For personal use only The purpose of the initial clinical trial is to gather information from stroke patients that allows refinement and selection of the optimal imaging algorithms as well as early data on correlation with CT and/or MRI FIRST UNIT INTERNAL VERIFICA
Slide 11: 2020 Target Milestones
2020 TARGET MILESTONES For personal use only Over next 6-12 Months Feedback from initial FDA pre- Further value-add product Pivotal clinical trial submission and development of development and commercial site selection regulatory approval plan partnerships Building of in-house engineering Developmen
Slide 12: Get in touch
www.emvision.com.au For personal use only GET IN TOUCH Dr Ron Weinberger Scott Kirkland CEO, EMvision Executive Director, EMvision E: E: skirkland@emvision.com.au rweinberger@emvision.com.au P: 02 8667 5337 P: 02 8667 5337
EMVision Medical Devices — Shareholder Meeting (November 2019) on 6ix